登台2024年ADA大会，中国减重降糖药物引人注目
Southwest Securities·2024-07-01 06:12
11 先为达 XW003 信达生物的玛仕度肽是一款GLP-1/GCCR双靶点激动剂，其三期临床研究GLORY-1及9mg剂量减重二期临床研究于本次ADA大 会披露临床数据。在三期临床研究中，玛仕度肽（4mg、6mg）及安慰剂组人群的32周体重下降比例分别为-10.72% vs - 13.14% vs -0.24%；在二期临床研究中，玛仕度肽（9mg）组体重相对于基线的平均百分比变化为-13.3%，而安慰剂组为2.1%。 ADA大会中国药物临床试验摘要概览 3 数据来源：ADA，西南证券整理 【 For orprinory versighting, weighted and waist crisematives restricts on anate colorantifer of financistions of superinting of muchtish of mg modelow were essessed expranc mazdutide 4 mg and 6 mg were pooled. § The percentage was colculated with the use of Rubin' ...